Q-omics provides the consensus-scored RPL32P21 profile across patient tissues and cancer cell-line models. RPL32P21 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPL32P21 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RPL32P21 protein abundance shows 16,106 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight CHOL, KIRC, and PDAC as cancer lineages where RPL32P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL32P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL32P21 survival associations across molecular data types. RPL32P21 RNA expression shows survival associations in the most cancer types (17), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL32P21 RNA expression–survival associations across cancer types. High RPL32P21 expression shows unfavorable associations in CHOL, OV and ACC, but favorable associations in COAD, BLCA and THYM. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify CHOL as the clearest survival context for RPL32P21 RNA expression.
This table summarizes RPL32P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL32P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL32P21 shows lower tumor expression in STAD and higher tumor expression in KIRC, LIHC, LUAD and PRAD. The KIRC box plot shows higher RPL32P21 RNA expression in tumor versus normal tissue (log2 FC = +0.072, t-test p < 0.001).
This table shows molecular features associated with RPL32P21 in patient tissues and cancer cell lines. In patient samples, RPL32P21 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
